588 results match your criteria hyperplasia overactive

Inhibition of LIM kinase reduces contraction and proliferation in bladder smooth muscle.

Acta Pharm Sin B 2021 Jul 7;11(7):1914-1930. Epub 2021 Jan 7.

Department of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.

Overactive bladder (OAB) is the most bothersome symptom in lower urinary tract symptoms (LUTS). Current pharmacologic treatment aims to inhibit detrusor contraction; however, shows unsatisfied efficacy and high discontinuation rate. LIM kinases (LIMKs) promote smooth muscle contraction in the prostate; however, their function in the bladder smooth muscle remains unclear. Read More

View Article and Full-Text PDF

Longitudinal Changes in Adiposity and Lower Urinary Tract Symptoms Among Older Men.

J Gerontol A Biol Sci Med Sci 2021 Aug 10. Epub 2021 Aug 10.

Oregon Health and Science University-Portland State University School of Public Health, Portland OR.

Background: Adiposity increases risk for male lower urinary tract symptoms (LUTS), although longitudinal studies have produced conflicting results. No prior studies have evaluated longitudinal associations of changes in adiposity with concurrent LUTS severity among older men.

Methods: We used repeated adiposity measurements from dual-energy x-ray absorptiometry (DXA), body mass index (BMI), and American Urological Association Symptom Index (AUASI) measured at four study visits over a 9-year period among 5949 men enrolled in the Osteoporotic Fractures in Men (MrOS) study. Read More

View Article and Full-Text PDF

Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.

Low Urin Tract Symptoms 2021 Jul 28. Epub 2021 Jul 28.

Department of Urology, Yonsei University College of Medicine, Seoul, South Korea.

Objective: Symptoms of male overactive bladder (OAB) may be caused by several systemic pathophysiological factors rather than a single-source etiology. We investigated the clinical factors associated with the severity of OAB symptoms in treatment-naïve men with coexisting benign prostatic hyperplasia.

Methods: We obtained records from a health promotion center database of male patients who visited between March 2019 and February 2020. Read More

View Article and Full-Text PDF

Concentration-dependent alpha-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate.

Front Pharmacol 2021 24;12:666047. Epub 2021 Jun 24.

Department of Urology, University Hospital, LMU Munich, Munich, Germany.

Mirabegron is available for treatment of storage symptoms in overactive bladder, which may be improved by β-adrenoceptor-induced bladder smooth muscle relaxation. In addition to storage symptoms, lower urinary tract symptoms in men include obstructive symptoms attributed to benign prostatic hyperplasia, caused by increased prostate smooth muscle tone and prostate enlargement. In contrast to the bladder and storage symptoms, effects of mirabegron on prostate smooth muscle contraction and obstructive symptoms are poorly understood. Read More

View Article and Full-Text PDF

Postoperative medical treatment of lower urinary tract symptoms after benign prostatic hyperplasia surgery. Are we underestimating the problem?

Curr Opin Urol 2021 Sep;31(5):451-455

Institute for Urology and Reproductive Health.

Purpose Of Review: The aim of this study was to determine whether well timed start of medical and surgical treatment of benign prostatic obstruction (BPO) influences the treatment's effectiveness and thus the patients' overall functional outcomes and quality of life.

Recent Findings: Pharmacological therapy even in high-volume (>80 cm3) BPH typically begins with α-blockers sole and only subsequently are 5ARI added. Several studies showed that acute urinary retention (AUR) developed more frequently in men who suffered severe lower urinary tract symptoms (LUTS) and who did not start combination therapy immediately. Read More

View Article and Full-Text PDF
September 2021


Georgian Med News 2021 Apr(313):7-12

2Hannover Medical School, Division of Surgery, Department of Urology & Urological Oncology; 5DIAKOVERE GmbH, Friederikenstft Lutheran Hospital, Department of Urology, Hannover, Germany.

Phosphodiesterase (PDE) enzymes are considered being key proteins in controlling the function of smooth musculature in the human urinary tract. The use of PDE inhibitors (PDE-Is) to treat erectile dysfunction and lower urinary tract symptomatology (LUTS) secondary to benign prostatic hyperplasia (BPH) is well established. It has been shown that PDE-Is can reverse the tension induced by means of muscarinergic agents of detrusor smooth muscle and enhance the production of cyclic nucleotides. Read More

View Article and Full-Text PDF

Does traditional pharmacotherapy augment behavioral modification in the treatment of nocturia?

Neurourol Urodyn 2021 06 11;40(5):1133-1139. Epub 2021 May 11.

Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.

Aims: To assess the efficacy of traditional first-line non-antidiuretic pharmacotherapy for nocturia in the real-world outpatient urology setting.

Methods: We retrospectively analyzed voiding diaries from adult men treated for lower urinary tract symptoms (LUTS) at an outpatient urology clinic to identify pairs of voiding diaries with ≥1 nocturnal void at baseline and a corresponding follow-up diary completed within 1 year. We compared the odds of nocturia improvement (decrease of ≥1 nocturnal void) in patients started on LUTS pharmacotherapy versus behavioral modification alone. Read More

View Article and Full-Text PDF

Comparison of Long-term Effect and Complications Between Holmium Laser Enucleation and Transurethral Resection of Prostate: Nations-Wide Health Insurance Study.

Urology 2021 Aug 29;154:300-307. Epub 2021 Apr 29.

Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. Electronic address:

Objective: To investigate and compare the postoperative efficacy and complications of the transurethral resection of prostate (TURP) and holmium laser enucleation (HoLEP) using the nationwide insurance database of Korea.

Methods: We created a cohort of benign prostatic hyperplasia (BPH) patients treated with TURP and HoLEP between 2011 and 2017 from the nationwide database of reimbursement. We compared the postoperative effects between the two surgical groups. Read More

View Article and Full-Text PDF

Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Curr Med Res Opin 2021 Aug 13;37(8):1303-1313. Epub 2021 May 13.

Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA.

Objectives: This study examined the incidence and predictors of antimuscarinic medication use including non-selective antimuscarinics among older adults with dementia and overactive bladder (OAB).

Methods: The study used a new-user cohort design involving older adults (≥65 years) with dementia and OAB based on 2013-2015 Medicare data. Antimuscarinics included non-selective (oxybutynin, tolterodine, trospium, fesoterodine) and selective (solifenacin, darifenacin) medications. Read More

View Article and Full-Text PDF

Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.

World J Urol 2021 Mar 31. Epub 2021 Mar 31.

Department of Urology, Careggi Hospital, University of Florence, San Luca Nuovo, Florence, Italy.

Purpose: Rezūm is the latest developed minimally invasive treatment for benign prostatic hyperplasia (BPH). We aimed to carefully assess the functional outcomes of patients treated with Rezūm for BPH.

Methods: We prospectively followed 135 consecutive patients treated by Rezūm at 5 institutions from June 2019 to August 2020. Read More

View Article and Full-Text PDF

Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical study.

Int J Clin Pract 2021 Jul 19;75(7):e14184. Epub 2021 Apr 19.

Department of Surgery, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.

Purpose: The efficacy and safety of βeta-3 agonists (Mirabegron 50 mg) have been sparingly assessed in the published English literature. We aim to do an efficacy-safety analysis of Mirabegron-Tamsulosin combination therapy vs tamsulosin-placebo monotherapy in a select subset of medication virgin Benign Prostatic Enlargement (BPE) patients with coexisting predominant non-neurogenic overactive bladder symptoms (OABS).

Methods: After prior written informed consent and IEC, 80 patients of uncomplicated BPE with coexisting non-neurogenic OABS and IPSS of >7 without contraindications to drug therapy were computer randomised/allocated to receive either[50 mg Mirabegron plus Tamsulosin 0. Read More

View Article and Full-Text PDF

Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study.

Eur Urol Focus 2021 Mar 20. Epub 2021 Mar 20.

Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy. Electronic address:

Background: Discrepancies exist between patient-reported storage phase symptoms severity and International Prostate Symptom Score (IPSS) scores.

Objective: To investigate whether the Overactive Bladder questionnaire (OABq) can detect further storage phase lower urinary tract symptoms (LUTS) among patients complaining solely of voiding LUTS based on the IPSS questionnaire, and to address the real-life impact of voiding LUTS towards patients' quality of life (QoL).

Design, Setting, And Participants: Data from 233 consecutive men seeking medical help for LUTS/benign prostate enlargement for the first time were analysed. Read More

View Article and Full-Text PDF

Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.

Urol Int 2021 9;105(9-10):817-825. Epub 2021 Mar 9.

Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.

Aim: To verify if the efficacy of the triple therapy with tamsulosin, dutasteride, and imidafenacin (TDI) is influenced by any background characteristics in patients with overactive bladder (OAB).

Methods: A subanalysis of data from the DIrecT study was conducted. Superiority of TDI over tamsulosin and dutasteride in terms of efficacy based on the Overactive Bladder Symptom Score (OABSS), total International Prostate Symptom Score (IPSS), IPSS quality of life index, and postvoid residual (PVR) was evaluated in binary subgroups. Read More

View Article and Full-Text PDF

Self-Management for Men With Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis.

Ann Fam Med 2021 Mar-Apr;19(2):157-167

Institute for Evidence-Based Healthcare, Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia.

Purpose: Lower urinary tract symptoms are very common in older men. We conducted a systematic review and meta-analysis to evaluate the effects of self-management interventions on these symptoms.

Methods: We included randomized controlled trials comparing the effect of self-management interventions (alone or combined with drug therapy) with usual care or drug therapy alone in men with lower urinary tract symptoms. Read More

View Article and Full-Text PDF
February 2020

Lifestyle in urology: Benign diseases.

Urologia 2021 Aug 12;88(3):163-174. Epub 2021 Feb 12.

Department of Urology, Agostino Gemelli Hospital Foundation - IRCCS, Catholic University Medical School, Rome, Italy.

Modifiable lifestyle-related risk factors are the object of increasing attention, with a view to primary and tertiary prevention, to limit the onset and development of diseases.Also in the urological field there is accumulating evidence of the relationship between urological diseases and lifestyle-related risk factors that can influence their incidence and prognosis. Risk factors such as nutrition, physical activity, sexual habits, tobacco smoking, or alcohol consumption can be modified to limit morbidity and reduce the social impact and the burdensome costs associated with diagnosis and treatment. Read More

View Article and Full-Text PDF

Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling.

Thorax 2021 04 4;76(4):326-334. Epub 2021 Feb 4.

Inserm UMR 1087, Nantes, France

Background: Severe asthma is a chronic lung disease characterised by inflammation, airway hyperresponsiveness (AHR) and airway remodelling. The molecular mechanisms underlying uncontrolled airway smooth muscle cell (aSMC) proliferation involved in pulmonary remodelling are still largely unknown. Small G proteins of the Rho family (RhoA, Rac1 and Cdc42) are key regulators of smooth muscle functions and we recently demonstrated that Rac1 is activated in aSMC from allergic mice. Read More

View Article and Full-Text PDF

Extensive impact of COVID-19 pandemic on pelvic floor dysfunctions care: A nationwide interdisciplinary survey.

Neurourol Urodyn 2021 02 25;40(2):695-704. Epub 2021 Jan 25.

Department of Obstetrics & Gynecology, Ospedale Maggiore di Lodi - ASST Lodi, Lodi, Italy.

Aims: To investigate the impact of COVID-19 pandemic on health-care provision to patients suffering from pelvic floor dysfunctions in Italy.

Methods: A retrospective web-based interdisciplinary survey was mailed by the Italian Society of Urodynamics to members involved in pelvic floor dysfunctions management from June 22, 2020 to July 17, 2020. The 84-item questionnaire investigated the period March-June 2020 (first epidemic wave) and showed high content validity. Read More

View Article and Full-Text PDF
February 2021

Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study.

Urology 2021 Jul 21;153:256-263. Epub 2021 Jan 21.

Department of Urology, Juntendo University, Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Objective: To investigate the efficacy and safety of vibegron add-on therapy in men with persistent storage symptoms receiving α-1 blockers or PDE5 inhibitor for benign prostatic hyperplasia and then determine the independent factors affecting the efficacy of vibegron.

Methods: Vibegron 50 mg was administered for 12 weeks to 42 patients (72.0 ± 8. Read More

View Article and Full-Text PDF

An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden.

Urology 2021 Jul 20;153:42-48. Epub 2021 Jan 20.

Birmingham/Atlanta Department of Veterans Affairs Geriatric Research, Education, and Clinical Center (GRECC), Birmingham, AL, and Decatur, GA; University of Alabama at Birmingham, Birmingham, AL.

Objective: To evaluate tamsulosin (α-blocker therapy) for male overactive bladder (OAB) and to examine if indicators of concomitant benign prostatic hyperplasia are associated with OAB symptom improvement.

Materials And Methods: This was a planned, exploratory analysis of a 4-week, α-blocker (tamsulosin 0.4 mg) run-in phase of the Male Overactive Bladder Trial in Veterans (MOTIVE). Read More

View Article and Full-Text PDF


Nihon Hinyokika Gakkai Zasshi 2020 ;111(1):1-8

Department of Urology, Nagakubo Hospital.

(Objective) Recently, lower urinary tract symptoms (LUTS) were reported to be associated with endothelial dysfunction. Endothelial function is non-invasively measured by flow-mediated dilation (FMD). As tadalafil has the potential to improve atherosclerosis, we evaluated the relationship between LUTS and endothelial function using FMD, and the effects of tadalafil. Read More

View Article and Full-Text PDF
February 2021

[Patient Background Factors Affecting Prescription Drugs for Male Lower Urinary Tract Symptoms: The Multicenter Study of Miyazaki Urological-Network Group].

Hinyokika Kiyo 2020 Dec;66(12):433-438

The Department of Urology, Faculty of Medicine, University of Miyazaki.

The present multicenter study performed by the MIYAZAKI UROLOGICAL-NETWORK GROUP involving patients from 32 hospitals in Miyazaki Prefecture demonstrates that an association exists between the use of prescription drugs for male lower urinary tract symptoms (MLUTS) and patient characteristics. Men aged ≥40 years who were prescribed at least one drug for MLUTS between April 1, 2014 and March 31, 2015 were prospectively recruited. In total, 2,295 patients with a median age of 72 years were enrolled. Read More

View Article and Full-Text PDF
December 2020

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy.

Ther Adv Urol 2020 Jan-Dec;12:1756287220974130. Epub 2020 Dec 18.

Department of Urology, Yonsei University Wonju College of Medicine, 20Ilsan-ro, Wonju-si, Kangwon-do, 220-701, South Korea.

Background: The aim of this study was to evaluate the change in lower urinary tract symptoms and quality of life (QoL) after combination therapy of solifenacin and mirabegron in patients with benign prostatic hyperplasia presenting with persistent storage symptoms after treatment with tamsulosin.

Material & Methods: We evaluated the International Prostatic Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), prostate-specific antigen, prostate volume, peak flow rate (Qmax), and post-voided residual volume (PVR) before and after treatment. Patients showing baseline OABSS ⩾3 were included and treated with tamsulosin 0. Read More

View Article and Full-Text PDF
December 2020

Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.

Curr Urol Rep 2021 Jan 7;22(1). Epub 2021 Jan 7.

Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.

Purpose Of Review: To review the efficacy and safety of mirabegron in men with overactive bladder (OAB) and benign prostatic hyperplasia (BPH).

Recent Findings: Numerous studies have shown mirabegron to be efficacious and safe in treating symptoms of OAB. More recent studies evaluating the use of mirabegron in men with OAB and BPH have also shown the medication to be effective with few adverse side effects when used as monotherapy or in combination therapy. Read More

View Article and Full-Text PDF
January 2021

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy.

Int Neurourol J 2020 Dec 31;24(4):365-374. Epub 2020 Dec 31.

Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.

Purpose: The aim of this meta-analysis was to evaluate the efficacy and safety of imidafenacin for overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving alpha-blocker monotherapy.

Methods: We performed a systematic research of the PubMed, Embase, and Cochrane Library databases, and searched for studies about alpha-blocker with or without imidafenacin treatment for OAB in patients with BPH. We also investigated the original references of the included texts. Read More

View Article and Full-Text PDF
December 2020

Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms.

Int Neurourol J 2021 Mar 31;25(1):69-76. Epub 2020 Dec 31.

The 2nd Department of Urology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Purpose: Several trials have shown that in men with overactive bladder (OAB) and benign prostate enlargement (BPE), the combination of an α-blocker with an anticholinergic is superior to α-blocker monotherapy. The purpose of this study is to explore whether urodynamic detrusor overactivity (DO) affects clinical outcomes in men with BPE and OAB.

Methods: This is a post hoc analysis of a prospective, randomized trial, designed to evaluate the changes of morphometric parameters of the prostate following monotherapy or combination therapy in men with BPE-OAB. Read More

View Article and Full-Text PDF

Night-Time Urinary Frequency Is Increased after the Great East Japan Earthquake along with Seasonal Variation: A Five-Year Longitudinal Study in Kesennuma City.

Tohoku J Exp Med 2020 12;252(4):329-337

Department of Urology, Tohoku University Graduate School of Medicine.

Disasters influence various health conditions; however, little has been reported about urinary symptoms. The objective of this study is to evaluate whether night-time urinary frequency was influenced by the Great East Japan Earthquake (GEJE) in March 2011. We also evaluated seasonal variation of night-time frequency, which may affect the primary objective. Read More

View Article and Full-Text PDF
December 2020

Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study.

Int J Urol 2020 Nov 16;27(11):974-980. Epub 2020 Aug 16.

Department of Urology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Objective: To evaluate functional outcomes over a year for benign prostatic hyperplasia treated with thulium laser enucleation of the prostate or bipolar transurethral resection of the prostate.

Methods: In this study, we prospectively included 140 patients who were treated for benign prostatic hyperplasia from April 2017 to February 2019. A randomization list was used for non-blind assignment to treatment groups (thulium laser enucleation of the prostate or bipolar transurethral resection of the prostate). Read More

View Article and Full-Text PDF
November 2020

[Male non-neurogenic overactive bladder].

V Phé X Gamé

Prog Urol 2020 Nov;30(14):880-886

Département d'urologie, transplantation rénale et andrologie, CHU Rangueil, université Paul-Sabatier, Toulouse, France.

Introduction: Male lower urinary tract symptoms (LUTS) and in particular overactive bladder (OAB) are a frequent reason for consultation in urology and have a significant functional impact in patients.

Objective: To synthesize current knowledge on non-neurogenic OAB in male patients.

Method: A systematic literature review based on Pubmed, Embase, Google Scholar was conducted in June 2020. Read More

View Article and Full-Text PDF
November 2020

Does Prostatic Urethral Lift Reduce Urinary Medications? Trends in Medical Treatment Before and After Prostatic Urethral Lift.

J Endourol 2021 05 20;35(5):657-662. Epub 2021 Jan 20.

New Jersey Urology, Voorhees, New Jersey, USA.

To analyze medications used to treat urinary symptoms in patients before and after prostatic urethral lift (PUL) and determine if there are any significant relationships between several patient factors and onset of overactive bladder (OAB) symptoms requiring treatment. A retrospective chart review of 226 patients who underwent PUL was performed. Data were collected on age, urinary medications, voiding questionnaires, and prostate volume from 6 months before to 6 months after the intervention. Read More

View Article and Full-Text PDF

New mouse model of underactive bladder developed by placement of a metal ring around the bladder neck.

Low Urin Tract Symptoms 2021 Apr 21;13(2):299-307. Epub 2020 Oct 21.

Department of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Objective: To develop a new mouse model of underactive bladder (UAB) caused by chronic bladder outlet obstruction (BOO).

Methods: BOO was created in 6-week-old male C57BL/6 mice using surgery to loosely place a silver jump ring around the bladder neck of each mouse. Micturition behavior (assessed with a metabolic cage) and cystometry were used to evaluate bladder function at 8 and 16 weeks after BOO. Read More

View Article and Full-Text PDF